Regarding CAD, a study based on biobanks and databases from the IMPROVE study—a prominent European prospective cohort study comprising high-risk individuals who were initially free of clinically overt cardiovascular disease—concluded that IL-5 is not useful as a biomarker for CAD [36]. This evidence concerns the gene IL5 and cardiovascular disorder.